Expert Analysis

Resistance and Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Resistance and Management of Treatment-Experienced Patients

CME Program Director: John P. Phair, MD

Faculty:

Daniel R. Kuritzkes, MD
Kathleen E. Squires, MD
Andrew R. Zolopa, MD

CREDIT INFORMATION

Release Date: 09/22/05

Expiration Date: 09/21/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the potential risks and benefits of treatment simplification and interruption in treatment-experienced patients.
Recount data on the efficacy of approved and investigational antiretrovirals in multiclass-experienced patients.
Describe strategies to reduce the frequency of drug resistance associated with prophylactic use of antiretrovirals in pregnancy.
Describe HAART regimens associated with increased risk of treatment failure.
Discuss data on the impact of baseline resistance mutations on treatment outcomes in patients initiating HAART.

Topics covered include:

New Insights Into the NYC Case
Transmitted Resistance in Treatment-Naive Patients in GS 934
High Virologic Failure Rate With Efavirenz/Tenofovir/Didanosine
Simplification to Boosted PI Monotherapy
Absence of Resistance After Virologic Failure on Saquinavir/Ritonavir
Further Analysis of Tipranavir/Ritonavir in Treatment-Experienced Patients
TMC114/Ritonavir in Treatment-Experienced Patients
Maintaining Lamivudine After Multiclass Failure
Reducing Resistance After Nevirapine Prophylaxis Against Mother-to-Child Transmission

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.